ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,581.30
0.15%
S&P ASX All Technology
2,975.00
0.21%
Brent Oil
83.565
0.03%
US Dollar vs AUD
1.53278
0.12%
Bitcoin
57,775.14
-0.79%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) News

INCY

Incyte (INCY)

Incyte Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INCY
DateTimeSourceHeadlineSymbolCompany
30/04/202421:00Business WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
24/04/202408:11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
24/04/202408:01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
23/04/202421:00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
11/04/202422:00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
01/04/202423:30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
30/03/202407:30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
11/03/202423:57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
11/03/202423:57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
11/03/202421:06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
11/03/202420:53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
11/03/202407:05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
11/03/202407:05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
05/03/202406:38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
05/03/202406:02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
05/03/202400:00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
01/03/202402:19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
29/02/202423:30GlobeNewswire Inc.Knight Therapeutics Announces Launch of Minjuvi® in BrazilNASDAQ:INCYIncyte Corporation
29/02/202401:11Business WireIncyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôteNASDAQ:INCYIncyte Corporation
28/02/202423:15Business WireIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hatNASDAQ:INCYIncyte Corporation
28/02/202408:08Business WireIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
17/02/202408:04Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:INCYIncyte Corporation
17/02/202404:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
17/02/202404:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
17/02/202404:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
17/02/202404:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
17/02/202404:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
17/02/202404:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
16/02/202400:00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
15/02/202404:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY

Your Recent History

ASX
NAB
National Australia Bank
NYSE
MRK
Merck
ASX
XMM
S&P ASX 300 Metals and M...
FX
AUDJPY
AUD vs Yen
NYSE
VZ
Verizon Communications
ASX
WBC
Westpac Banking
CCOM
SILVER
SILVER
ASX
FMG
Fortescue
ASX
TLS
Telstra
ASX
WES
Wesfarmers
ASX
WPL
Woodside Petroleum
ASX
WOW
Woolworths
ASX
WDC
Westfield
ASX
NCM
Newcrest Mining
ASX
XTO
S&P ASX 100
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved